| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 14, 2026 | Nitro Launches Nitro Automate, Integrating Intelligent Document Automation Into Any Workflow, System, and AI Agent | Nitro Software, a global provider of PDF, eSign, and AI-powered document automation solutions, today announced early access availability of Nitro Automate, an intelligent document automation solution that embeds Nitro’s enterprise-grade doc... |
| May 6, 2026 | Nitro Releases MCP Connector for Claude AI, Introduces Document Automation Solution | Nitro Software, a trusted global provider of PDF, eSign, and AI-powered document automation solutions, today announced early access to Nitro MCP, a Model Context Protocol (MCP) connector that brings Nitro’s document engine directly into Cla... |
| Dec 8, 2021 | Strong Roots and McCain Announce Partnership to Grow Plant-Based Product Range Globally | TORONTO and NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Strong Roots, a leading plant-based frozen food company and McCain Foods, the family-owned world leader in frozen potato specialties and appetizers, today announced a strategic partnership,... |
| Dec 8, 2021 | Strong Roots and McCain Announce Partnership to Grow Plant-Based Product Range Globally | Strong Roots will remain independent with McCain Foods investing $55MN to help the company to grow and further drive its work in sustainability
TORONTO and NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Strong Roots, a leading plant-based frozen fo... |
| Dec 8, 2021 | Strong Roots and McCain Announce Partnership to Grow Plant-Based Product Range Globally | TORONTO and NEW YORK, Dec. 8, 2021 /CNW/ -- Strong Roots, a leading plant-based frozen food company and McCain Foods, the family-owned world leader in frozen potato specialties and appetizers, today announced a strategic partnership, with M... |
| Nov 16, 2021 | MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures | NEW YORK, Nov. 16, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD; NEO: MMED; DE: MMQ; the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce it has launched re... |
| Nov 15, 2021 | MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline | NEW YORK, Nov. 15, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021.... |
| Nov 15, 2021 | MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline | NEW YORK, Nov. 15, 2021 /CNW/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021.
Third ... |
| Nov 15, 2021 | MindMed Announces Financial Results for the Third Quarter 2021 and Business Highlights; Cash Balance of $145.9 USD ($185.4 CAD) to Execute on Diverse Clinical Pipeline | NEW YORK, Nov. 15, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended September 30, 2021.... |
| Oct 26, 2021 | MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program | NEW YORK, Oct. 26, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ); the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion of its p... |
| Oct 26, 2021 | MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program | NEW YORK, Oct. 26, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ); the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion o... |
| Oct 26, 2021 | MindMed Expands its Drug Development Pipeline with Launch of R(-)-MDMA Program | NEW YORK, Oct. 26, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ); the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce an expansion o... |
| Oct 13, 2021 | MindMed Joins Clinical Trials Transformation Initiative | NEW YORK, Oct. 13, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Transformati... |
| Oct 13, 2021 | Mind Medicine MindMed : MindMed Joins Clinical Trials Transformation Initiative | NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Trans... |
| Oct 13, 2021 | MindMed Joins Clinical Trials Transformation Initiative | NEW YORK, Oct. 13, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has joined the Clinical Trials Trans... |
| Oct 5, 2021 | Mind Medicine MindMed : MindMed Announces Strategic Research Collaboration with Sphere Health | NEW YORK, Oct. 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to partner with Sphere Hea... |
| Sep 30, 2021 | Mind Medicine MindMed : MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton | NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to ... |
| Sep 21, 2021 | Mind Medicine MindMed : MindMed Announces Participation at Upcoming Investor Conferences | NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announces that Robert Barrow,... |
| Sep 2, 2021 | MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes | NEW YORK, Sept. 2, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a lea... |
| Sep 2, 2021 | MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes | NEW YORK, Sept. 2, 2021 /CNW/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading cl... |
| Aug 24, 2021 | Forian : MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders | NEW YORK, Aug. 24, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, has agreed to work with Forian Inc. ... |
| Aug 12, 2021 | MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline | NEW YORK, Aug. 12, 2021 /CNW/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended June 30, 2021.
Q2 2021... |
| Aug 12, 2021 | MindMed Announces 2021 Q2 Financial Results; Cash Balance of $157 USD Million ($195 CAD Million) to Execute on Diverse Clinical Pipeline | NEW YORK, Aug. 12, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended June 30, 2021.
... |
| Jul 28, 2021 | Mind Medicine MindMed : MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT | NEW YORK, July 28, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the start of a Phase 1 clinical trial to assess the safety, ph... |
| Jul 8, 2021 | Mind Medicine MindMed : MindMed Announces Partnership with Datavant, a Leading Health Data Connectivity Company | NEW YORK, July 8, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, and Datavant, Inc. ("Datavant"), a leader in helping healthcare organizations ... |
| Jul 1, 2021 | bolttech achieves unicorn status following US$180 million series A, the largest ever for an insurtech | NEW YORK and SINGAPORE, July 1, 2021 /PRNewswire/ -- bolttech, one of the fastest growing international insurtech companies, today announced the completion of an oversubscribed US$180 million series A funding round led by Activant Capital G... |
| Jul 1, 2021 | bolttech : achieves unicorn status following US$180 million series A, the largest ever for an insurtech | NEW YORK and SINGAPORE, July 1, 2021 /PRNewswire/ -- bolttech, one of the fastest growing international insurtech companies, today announced the completion of an oversubscribed US$180 million series A funding round led by Activant Capital G... |
| Jun 9, 2021 | Mind Medicine MindMed : MindMed Announces Chief Executive Officer Transition | NEW YORK, June 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines... |
| Jun 9, 2021 | MIND MEDICINE (MINDMED) INC.
Mind Medicine MindMed : MindMed Announces Chief Executive Officer Transition | NEW YORK, June 9, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading clinical-stage pharmaceutical company and pioneer in the field of psychedelic inspired medicines... |
| May 27, 2021 | MindMed announces shareholder Meeting Results | NEW YORK, May 27, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that each of the resolutions put before the annual and specia... |
| May 27, 2021 | MindMed announces shareholder Meeting Results | NEW YORK, May 27, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) ("MindMed" or the "Company") is pleased to announce that each of the resolutions put before the annual and special meeti... |
| May 24, 2021 | NEXTAGE THERAPEUTICS LTD
Nextage Therapeutics : MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System | NEW YORK, May 24, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD, NEO: MMED, DE: MMQ), a leading clinical stage psychedelic medicine company, and Nextage Therapeutics (TASE: NXTG), an Israeli innovative drug development company, announce the ex... |
| May 20, 2021 | MIND MEDICINE (MINDMED) INC.
Mind Medicine MindMed : MindMed Announces the Approval of Mescaline Study | BASEL, Switzerland, May 20, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic medicine company, announced today the approval by the local Swiss ethics committee of the first clinical tri... |
| May 17, 2021 | MIND MEDICINE (MINDMED) INC.
Mind Medicine MindMed : MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical Trial | MindMed Finalizes Clinical Development Approach for LSD Targeting Generalized Anxiety Disorder as Initial Indication
NEW YORK, May 17, 2021 /PRNewswire/ -- MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading clinical stage psychedelic m... |
| May 14, 2021 | MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline | NEW YORK, May 14, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed'' or the "Company") (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its quarterly financial results fo... |
| May 14, 2021 | MIND MEDICINE (MINDMED) INC.
Mind Medicine MindMed : MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline | NEW YORK, May 14, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed'' or the "Company") (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its quarterly financial res... |
| May 14, 2021 | MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline | NEW YORK, May 14, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed'' or the "Company") (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its quarterly financial res... |
| May 14, 2021 | Mind Medicine MindMed : MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical Pipeline | NEW YORK, May 14, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed'' or the "Company") (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, has announced its quarterly financial res... |
| May 5, 2021 | MIND MEDICINE (MINDMED) INC.
Mind Medicine MindMed : MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics | NEW YORK, May 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") (NASDAQ: MNMD) (NEO: MMED), (DE: MMQ), a leading psychedelic-inspired medicine company announces the launch of its Project A... |
| Apr 5, 2021 | MIND MEDICINE (MINDMED) INC.
Mind Medicine MindMed : MindMed Announces the Publication of New Data on Personalized MDMA Dosing | BASEL, Switzerland, April 5, 2021 /PRNewswire/ -- MindMed (NEO: MMED) (OTCQB: MMEDF) (DE: MMQ), a leading clinical-stage psychedelic medicine biotech company, announced the publication of the first study on MDMA dosing optimization using pe... |
| Mar 30, 2021 | MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD ($203 million CAD) to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform | Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million USD ($30.5 million CAD) for year ended December 31, 2020
NEW YORK, March 30, 2021 /CNW/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Company"... |
| Mar 30, 2021 | MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD ($203 million CAD) to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform | Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million USD ($30.5 million CAD) for year ended December 31, 2020
NEW YORK, March 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Compan... |
| Mar 30, 2021 | MindMed Announces 2020 Year-End Financial Results; Current Cash Balance of $161 million USD ($203 million CAD) to Support Drug Development Pipeline and Creation of Psychedelic Medicine Tech Platform | Net Cash Used in Operating Activities (Total Cash Burn) of $24.2 million USD ($30.5 million CAD) for year ended December 31, 2020
NEW YORK, March 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. ("MindMed" or the "Compan... |
| Mar 29, 2021 | MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board | Dr. Robert C. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences, Director of the Nancy Pritzker Laboratory and Deputy Director of the Wu Tsai Neurosciences Institute at Stanford University
NEW YORK, March 29, 2021 /CNW... |
| Mar 29, 2021 | MindMed Announces the Addition of Stanford University Neuroscientist as Chair of the Scientific Advisory Board | Dr. Robert C. Malenka is the Pritzker Professor of Psychiatry and Behavioral Sciences, Director of the Nancy Pritzker Laboratory and Deputy Director of the Wu Tsai Neurosciences Institute at Stanford University
NEW YORK, March 29, 2021 /PRN... |
| Mar 23, 2021 | Counterpart Launches First of Its Kind Insurtech in Partnership With Markel and $10M in Funding, Led by Valor Equity Partners | LOS ANGELES--(BUSINESS WIRE)--Mar 23, 2021--
Counterpart, the insurtech using technology and data to transform the $10bn management liability insurance market, has raised $10m in funding led by Valor Equity Partners, early backers of pionee... |
| Mar 22, 2021 | MindMed Announces Inclusion in FTSE Russell Indexes | NEW YORK, March 22, 2021 /CNW/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company announced that effective as of Friday March 19th, 2021, MindMed has been added to the FTSE Global Micro-Cap Ind... |
| Mar 22, 2021 | MindMed Announces Inclusion in FTSE Russell Indexes | NEW YORK, March 22, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company announced that effective as of Friday March 19th, 2021, MindMed has been added to the FTSE Global Micro-... |
| Feb 18, 2021 | MIND MEDICINE (MINDMED) INC.
Mind Medicine MindMed : MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company | Acquisition will help build a full stack digital mental health platform for psychedelic medicines; Ex-Pfizer Digital Medicine Executive Dr. Daniel R. Karlin M.D. M.A. and former Google AI/ML industry veteran Bradford Cross added to MindMed ... |
| Feb 18, 2021 | Mind Medicine MindMed : MindMed Reaches Agreement to Acquire HealthMode, a Leading Machine Learning Digital Medicine Company | Acquisition will help build a full stack digital mental health platform for psychedelic medicines; Ex-Pfizer Digital Medicine Executive Dr. Daniel R. Karlin M.D. M.A. and former Google AI/ML industry veteran Bradford Cross added to MindMed ... |
| Jan 20, 2021 | MIND MEDICINE (MINDMED) INC.
Mind Medicine MindMed : MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD | BASEL, Switzerland, Jan. 20, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced today the start of the first ever clinical trial measuring and evaluating MDMA and L... |
| Jan 20, 2021 | Mind Medicine MindMed : MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD | BASEL, Switzerland, Jan. 20, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company, announced today the start of the first ever clinical trial measuring and evaluating MDMA and L... |
| Aug 5, 2020 | US tech needs a pivot to survive | James Stranko Contributor
James Stranko is a writer and independent advisor to American tech companies expanding abroad. He was on the founding team of Fuel, McKinsey’s practice serving VC firms and pre-IPO tech leaders.
Daire Hickey Contri... |
